Abstract:Background: The relationship between cirrhosis and breast cancer treatment and outcomes has not been specifically explored. We evaluated the association between cirrhosis and surgical outcomes in female patients with breast cancer. Methods: We performed a retrospective cohort study of female patients undergoing surgery for breast cancer between 2007-2018 using health administrative data from Ontario, Canada. Breast cancer surgeries were captured using Canadian Classification of Health Intervention codes. Patients with cirrhosis were identified using validated coding definitions. Overall and cancer-specific survival from time of surgery to December 2021 was compared between patients with and without cirrhosis using Kaplan-Meier survival analysis. Modified Poisson regression, chi-square and ANOVA were used to assess the association between cirrhosis and 90-day post-operative mortality, post-operative complications, length of hospital stay, intensive care unit (ICU) admission, and post-operative hepatic decompensation within 6 months. Results: A total of 83,880 females with breast cancer undergoing surgery were identified with 910 (1%) having cirrhosis. The median age at diagnosis was 65 (IQR 57-72) in patients with cirrhosis and 61 (IQR 51-71) in those without (p< 0.001). The most common etiology of cirrhosis was non-alcoholic fatty liver disease (n = 602, 66%) followed by alcohol-related (n =144, 16%) with n=27 (3%) having a history of decompensation within two years prior to surgery. Model for end stage liver disease score (MELD-Na) was available in 24% (n = 218), with a median score of 8 (IQR 6 – 11). Patients with cirrhosis had similar breast cancer stage at diagnosis as patients without cirrhosis (47% stage I, 38% stage 2, 11% stage 3, and 0.5% stage 4) with the most common type of surgical procedure being lumpectomy (71%) in both groups. Use of pre-operative chemotherapy was less common in patients with cirrhosis (5.9% vs 7.9%, p=0.026). Post-operative radiation and chemotherapy within 6-months after surgery was lower in patients with cirrhosis (56.8% vs 63.7%, p< 0.001 and 48.4% vs 52.2%, p=0.019, respectively). Patients with cirrhosis had higher 90-day post-operative mortality compared to those without (1.4% vs 0.3%, p < 0.001). After adjusting for age, income quintile, and breast cancer surgery, cirrhosis was independently associated with 90-day post-operative mortality (RR, 4.1; 95% CI 2.4-6.8). Patients with cirrhosis had a higher prevalence of incision complications (6.4% vs 4.6%, p= 0.007) and blood transfusions (2.9% vs 1.1%, p < 0.001), but similar rates of surgical site infections (6.4% vs 5.3%, p=0.138) and venous thromboembolism (0.3% vs 0.5%, p=0.5). Re-operation was slightly higher in patients without cirrhosis (3.2% vs 4.6%, p=0.05). Length of hospital stay was 2 days in patients with cirrhosis and 1.3 days for patients without (p < 0.001); ICU admission was more likely in patients with cirrhosis (1.8% vs 0.9%, p=0.008); and 18 (2%) patients with cirrhosis developed post-operative hepatic decompensation within 6 months. Survival in patients with cirrhosis was lower than those without (5-year OS 77% vs 87%, p< 0.0001); stage 0/I (83% vs 94%, p< 0.05), stage II (75% vs 87%, p< 0.05), stage III (62% vs 73%, p< 0.05), stage IV (40% vs 40%). Cancer-specific survival was also lower in patients with cirrhosis (5-year CSS 88% vs 91%, p=0.017). Conclusion: This large population-based study demonstrates that, compared to patients without cirrhosis, patients with cirrhosis are older with similar stage at diagnosis, but are somewhat less likely to receive adjuvant therapies. While they have slightly higher risks of certain post-operative complications and lower overall and cancer-specific survival, their outcomes remain favourable and should be considered for curative-intent therapies. Citation Format: Manisha Jogendran, Jennifer Flemming, Maya Djerboua, Shaila Merchant, Sean Bennett. Cirrhosis is associated with worse post-operative survival among patients with breast cancer: a population-based study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl) nr PO3-18-01.

[Five Cases of Pseudocirrhosis during Eribulin Treatment for Breast Cancer]

The Clinical Features and Outcomes of Pseudocirrhosis in Breast Cancer

Acute-on-chronic liver failure following eribulin treatment for metastatic breast cancer: a case report

Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature

[Effectiveness of eribulin chemotherapy for squamous cell carcinoma of the breast]

Eribulin for heavily pre-treated metastatic breast cancer patients

[Multicenter Real World Study on the Efficacy and Safety of Eribulin for the Treatment of Advanced Breast Cancer].

A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

Abstract PO2-15-03: Platelet-to-lymphocyte ratio in patients with metastatic breast cancer treated with eribulin

A case of Stewart-Treves syndrome occurring in the abdominal wall successfully treated with eribulin: A case report

Examination of the clinical efficacy of eribulin and trastuzumab in HER2-positive recurrent breast cancer

Two staged phase II clinical trial of Eribulin monotherapy in advanced or recurrent cervical cancer

Abstract P2-20-17: Eribulin is an immune potentiator in breast cancer by up-regulation of human leukocyte antigen class I

Liver cirrhosis following oxaliplatin-based adjuvant chemotherapy for rectal cancer

ERCP in Patients with Liver Cirrhosis: an Analysis of 156 Cases

Eribulin Mesylate in Treated Metastatic Breast Cancer Patients: A Retrospective Study of Tumor Response and Adverse Effects

Abstract PO3-18-01: Cirrhosis is associated with worse post-operative survival among patients with breast cancer: a population-based study

Abstract PO5-05-11: The effect of eribulin treatment for patients with HER2-low breast cancer

Abstract PO2-15-09: Immune related cell fraction in peripheral blood and outcomes of advanced breast cancer patients treated with Eribulin

Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-Kinase inhibitor treatment for metastatic breast cancer

Real-world effectiveness of eribulin in heavily pretreated patients with metastatic breast cancer in China: A multicenter retrospective study.